Two's a Crowd: Versartis Raises $21 Million Series B, Cleaves Off Diabetes Asset to Form Diartis Pharma

Citing different financial needs, Versartis' backers have created Diartis to take its GLP-1 molecule to proof of concept, while Versartis focuses on human growth hormone.